Â鶹ӳ»­

Research Lab

Yan F, Jiang V, Jordan A, et al., Wang M: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma. Exp Hematol Oncol 13:14, 2024;  

Liu Y, Yan F, Jiang VC, et al., Wang M: Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma. Haematologica 108:1412-1416, 2023;

Jiang VC, Liu Y, Lian J, et al., Wang M: Co-targeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. J Clin Invest 133:e165694, 2023;

Li L, Nie L, Jordan A, et al., Wang M, Jiang VC: Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica 108:1616-1627, 2022;

Jiang VC, Liu Y, Jordan A, et al., Wang M: Targeting Fc¦ÃRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. J Hematol Oncol 15:42, 2022;

Jiang VC, Hao D, Jain P, et al., Wang M: TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer 21:185, 2022;

Jiang VC, Liu Y, Jordan A, et al., Wang M: The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol 14:132, 2021;

Hill HA, Qi X, Jain P, et al., Wang ML: Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv 4:2927-2938, 2020;

Guo WH, Qi X, Yu X, et al., Wang ML, Wang J: Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. Nat Commun 11:4268, 2020;

Zhang L, Yao Y, Zhang S, et al., Wang ML: Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med 11:eaau1167, 2019;

Guo H, Zeng D, Zhang H, et al., Wang ML: Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene 38:1802-1814, 2019;

Pham LV, Huang S, Zhang H, et al., Wang ML: Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res 24:3967-3980, 2018;

Lee J, Zhang LL, Wu W, et al., Wang ML, Wang YL: Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv 2:2039-2051, 2018;

Balaji S, Ahmed M, Lorence E, et al., Wang ML: NF-¦ÊB signaling and its relevance to the treatment of mantle cell lymphoma. J Hematol Oncol 11:83, 2018;

Zhang L, Nomie K, Zhang H, et al., Wang ML: B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin Cancer Res 23:4212-4223, 2017;

Wang M, Zhang L, Han X, et al.: A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 14:2154-60, 2008;

Clinical

Wang M, Siddiqi T, Gordon LI et al.: Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma (MCL): Primary analysis of the MCL cohort from TRANSCEND NHL 001, a Phase I multicenter seamless design study. J Clin Oncol (in press):101200jco2302214, 2023;

Wang M, Munoz J, et al.: Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 41:555-567, 2023;

Wang ML, Jurczak W, Zinzani PL, et al.: Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol 41:3988-3997, 2023;

Wang M, Jurczak W, Trn¨§n? M, et al.: Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: primary analysis results from the randomized Phase 3 Sympatico study. Blood 142(Suppl 1):LBA-2, 2023;

Wang Y, Jain P, Locke FL, et al., Wang ML, Jain MD: Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: Results from the US Lymphoma CAR T Consortium. J Clin Oncol JCO2201797, 2023;

Wang ML, Barrientos JC, Fruman RR, et al.: Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid 1:2022;

Jain P, Wang ML: Mantle cell lymphoma in 2022 ¨C A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol 97:638-656, 2022;

Mato AR, Shah NN, Jurczak W, et al., Wang M: Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet 397:892-901, 2021;

Wang M, Ramchandren R, et al.: Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol 14:179, 2021

Wang M, Munoz J, Goy A, et al.: KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382:1331-1342, 2020;

Pham LV, Huang S, et al., Wang M: Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res 24:3967-3980, 2018;

Wang M, Rule S, Zinzani PL, et al.: Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391:659-667, 2018;

Wang ML, Rule S, Martin P, et al.: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507-16, 2013;